Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model

Tumour-associated neutrophils (TANs) can support tumour growth by suppressing cytotoxic lymphocytes. AT-RvD1 is an eicosanoid that can antagonise neutrophil trafficking instigated by ALX/FPR2 ligands such as serum amyloid A (SAA). We aimed to establish whether SAA and ALOX5 expression associates wit...

Full description

Bibliographic Details
Main Authors: Amanda Vannitamby, Mohamed I. Saad, Christian Aloe, Hao Wang, Beena Kumar, Ross Vlahos, Stavros Selemidis, Louis Irving, Daniel Steinfort, Brendan J. Jenkins, Steven Bozinovski
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/13/3224
id doaj-1f6ad663d34c4be7828852cf39ea4882
record_format Article
spelling doaj-1f6ad663d34c4be7828852cf39ea48822021-07-15T15:31:38ZengMDPI AGCancers2072-66942021-06-01133224322410.3390/cancers13133224Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma ModelAmanda Vannitamby0Mohamed I. Saad1Christian Aloe2Hao Wang3Beena Kumar4Ross Vlahos5Stavros Selemidis6Louis Irving7Daniel Steinfort8Brendan J. Jenkins9Steven Bozinovski10School of Health & Biomedical Sciences, RMIT University, Bundoora 3083, AustraliaCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton 3168, AustraliaSchool of Health & Biomedical Sciences, RMIT University, Bundoora 3083, AustraliaSchool of Health & Biomedical Sciences, RMIT University, Bundoora 3083, AustraliaDepartment of Anatomical Pathology, Monash Health, Clayton 3168, AustraliaSchool of Health & Biomedical Sciences, RMIT University, Bundoora 3083, AustraliaSchool of Health & Biomedical Sciences, RMIT University, Bundoora 3083, AustraliaDepartment of Respiratory Medicine, Royal Melbourne Hospital, Parkville 3050, AustraliaDepartment of Respiratory Medicine, Royal Melbourne Hospital, Parkville 3050, AustraliaCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton 3168, AustraliaSchool of Health & Biomedical Sciences, RMIT University, Bundoora 3083, AustraliaTumour-associated neutrophils (TANs) can support tumour growth by suppressing cytotoxic lymphocytes. AT-RvD1 is an eicosanoid that can antagonise neutrophil trafficking instigated by ALX/FPR2 ligands such as serum amyloid A (SAA). We aimed to establish whether SAA and ALOX5 expression associates with TANs and investigate the immunomodulatory actions of AT-RvD1 in vivo. MPO-positive neutrophils were quantified in tumour blocks from lung adenocarcinoma (<i>n</i> = 48) and control tissue (<i>n</i> = 20) by IHC. Tumour expression of SAA and ALOX5 were analysed by RTqPCR and an oncogenic <i>Kras<sup>G12D</sup></i> lung adenocarcinoma mouse model was used to investigate the in vivo efficacy of AT-RvD1 treatment. ALOX5 expression was markedly reduced in lung adenocarcinoma tumours. The SAA/ALOX5 ratio strongly correlated with TANs and was significantly increased in tumours harbouring an oncogenic <i>KRAS</i> mutation. AT-RvD1 treatment reduced tumour growth in <i>Kras<sup>G12D</sup></i> mice, which was accompanied by suppressed cellular proliferation within parenchymal lesions. In addition, AT-RvD1 significantly reduced the neutrophil to lymphocyte ratio (NLR), an established prognostic marker of poor survival in adenocarcinoma. This study identifies a novel molecular signature whereby elevated levels of SAA relative to ALOX5 favour accumulation of TANs. Furthermore, the ALOX5/5-LO enzymatic product, AT-RvD1, markedly reduced the NLR and suppressed tumour growth in <i>Kras<sup>G12D</sup></i> mice.https://www.mdpi.com/2072-6694/13/13/3224lung canceradenocarcinomaneutrophilsresolutioninflammationALOX5
collection DOAJ
language English
format Article
sources DOAJ
author Amanda Vannitamby
Mohamed I. Saad
Christian Aloe
Hao Wang
Beena Kumar
Ross Vlahos
Stavros Selemidis
Louis Irving
Daniel Steinfort
Brendan J. Jenkins
Steven Bozinovski
spellingShingle Amanda Vannitamby
Mohamed I. Saad
Christian Aloe
Hao Wang
Beena Kumar
Ross Vlahos
Stavros Selemidis
Louis Irving
Daniel Steinfort
Brendan J. Jenkins
Steven Bozinovski
Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model
Cancers
lung cancer
adenocarcinoma
neutrophils
resolution
inflammation
ALOX5
author_facet Amanda Vannitamby
Mohamed I. Saad
Christian Aloe
Hao Wang
Beena Kumar
Ross Vlahos
Stavros Selemidis
Louis Irving
Daniel Steinfort
Brendan J. Jenkins
Steven Bozinovski
author_sort Amanda Vannitamby
title Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model
title_short Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model
title_full Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model
title_fullStr Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model
title_full_unstemmed Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model
title_sort aspirin-triggered resolvin d1 reduces proliferation and the neutrophil to lymphocyte ratio in a mutant kras-driven lung adenocarcinoma model
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-06-01
description Tumour-associated neutrophils (TANs) can support tumour growth by suppressing cytotoxic lymphocytes. AT-RvD1 is an eicosanoid that can antagonise neutrophil trafficking instigated by ALX/FPR2 ligands such as serum amyloid A (SAA). We aimed to establish whether SAA and ALOX5 expression associates with TANs and investigate the immunomodulatory actions of AT-RvD1 in vivo. MPO-positive neutrophils were quantified in tumour blocks from lung adenocarcinoma (<i>n</i> = 48) and control tissue (<i>n</i> = 20) by IHC. Tumour expression of SAA and ALOX5 were analysed by RTqPCR and an oncogenic <i>Kras<sup>G12D</sup></i> lung adenocarcinoma mouse model was used to investigate the in vivo efficacy of AT-RvD1 treatment. ALOX5 expression was markedly reduced in lung adenocarcinoma tumours. The SAA/ALOX5 ratio strongly correlated with TANs and was significantly increased in tumours harbouring an oncogenic <i>KRAS</i> mutation. AT-RvD1 treatment reduced tumour growth in <i>Kras<sup>G12D</sup></i> mice, which was accompanied by suppressed cellular proliferation within parenchymal lesions. In addition, AT-RvD1 significantly reduced the neutrophil to lymphocyte ratio (NLR), an established prognostic marker of poor survival in adenocarcinoma. This study identifies a novel molecular signature whereby elevated levels of SAA relative to ALOX5 favour accumulation of TANs. Furthermore, the ALOX5/5-LO enzymatic product, AT-RvD1, markedly reduced the NLR and suppressed tumour growth in <i>Kras<sup>G12D</sup></i> mice.
topic lung cancer
adenocarcinoma
neutrophils
resolution
inflammation
ALOX5
url https://www.mdpi.com/2072-6694/13/13/3224
work_keys_str_mv AT amandavannitamby aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT mohamedisaad aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT christianaloe aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT haowang aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT beenakumar aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT rossvlahos aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT stavrosselemidis aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT louisirving aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT danielsteinfort aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT brendanjjenkins aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
AT stevenbozinovski aspirintriggeredresolvind1reducesproliferationandtheneutrophiltolymphocyteratioinamutantkrasdrivenlungadenocarcinomamodel
_version_ 1721299878684917760